Skinbiotherapeutics Share Discussion Threads

[nik7907] 04/12/2020 19:55

I also thought the Croda deal was going to start producing in 2nd half 2021. Not sure where it was mentioned, but am pretty sure it was.

[lovewinshatelosses] 04/12/2020 19:33

Commercialisation in 2021 is what I expect to see. I think the market is going to hit us next week, but I hope not. I have had enough 'top up opportunities' for one year. Anyway, it's Friday night! Good weekend all.

[fungusresearch] 04/12/2020 19:32

An excellent comment where the only minor correction is to the grammar. If "you" is replaced by "us" then it becomes exceptional.
No, it;s just done to keep mushrooms like us covered in the brown stuff and hence in the dark

[aquaesulis01] 04/12/2020 19:27

No, it;s just done to keep mushrooms like you covered in the brown stuff and hence in the dark

[fungusresearch] 04/12/2020 19:19

We would wonder why the shares presentation was done pre-results, when most respectable would wait a few days and present post results when more pertinent and accurate Q's can be asked, applied to the placing timing and even more Q's appear. Done for a reason? The CEO has been trained admirably well, I wonder by whom? Maybe the microbiome leaves a bad feeling in the gut?

[aquaesulis01] 04/12/2020 19:10

You need to learn how to read the RNS properly "First commercial deals signed across two technology channels - skin care and food supplement
Active skin care ingredient development on track with partner, Croda plc, with commercialisation expected in 2022
Unable to pursue its originally proposed human study because of COVID-19, the management adapted quickly to the situation and established a protocol for, and is proceeding with, a 'self-managed' food supplement study. Participants will be invited to participate in a human study in which they will be provided with samples of AxisBiotix™Ps to self-administer over an eight-week period. They will be asked to track the impact of the food supplement on their skin condition themselves. Participants will submit their findings on a periodic basis through a bespoke mobile device app, thus avoiding the need for clinical attendance. This will accelerate the timing of readout compared to the previously envisaged conventional study. As a result, if the findings are positive, this will allow for a significantly earlier commercial launch than originally planned. The Company anticipates the trial commencing in Q1 2021.
Looking forward to the new financial year, as Croda continues to progress the pathway of the SkinBiotix® technology as a cosmetic ingredient, a key focus for the Company will be the AxisBiotix™ programme targeting psoriasis. Here the Company is seeking to initiate and complete a 'self-managed' human study in Q1 2021 and, subject to a positive readout, commence commercialisation. This is an accelerated timeframe to that originally anticipated but equally presents an opportunity for a more rapid route to revenue generation."

In other words, subject to a satisfactory trial expect commercialisation of axisBiotix in 2021!

[lovewinshatelosses] 04/12/2020 18:50

Oh dear. At least those directors transferred most of those shares into their ISA's. It does feel like it's become a bottom draw share now and I admit, I'm also disappointed with the first RNS regarding the timeframe.
Oh well, let's see what the market decides next week. What is your take shrewdie, mada and nobby?

[fungusresearch] 04/12/2020 18:10

Commendable comment gary. ----shocking behaviour with an obvious pre placing pump& ramp and now the truth comes out. How do so many CEOs get away with obvious lies and deceit?

[gary hindsight] 04/12/2020 16:35

Very disappointed with comment on commercialisation in 2022. Not expected that at all based on interviews etc

[nobbygnome] 04/12/2020 13:29

Yes buywell is a troll of the worst type and is best avoided. As Troy says his predictions and postitions on companies are absolutely appalling. I could give you a very long list of where he has called things wrong.

[troy holton] 04/12/2020 12:33

For those that don’t know about Buywell (occasionally referred to as “sellbadlyR21;) it pops up on various sites, often refers to itself in the 3rd person, and always posts nonsense. Best to either totally ignore or do the exact opposite of what it suggests.

[madaboutmed] 04/12/2020 10:42

Would you be happier if they spent no money at all and made no progress? They have delivered on everything they said they would and are making great progress in a time when many companies are failing.

[madaboutmed] 04/12/2020 10:42

That was intended for buywell. Apologies

[madaboutmed] 04/12/2020 10:42

Would you be happier if they spent no money at all and made no progress? They have delivered on everything they said they would and are making great progress in a time when many companies are failing.

[atlantic57] 04/12/2020 09:07

Buy well the key driver here is the potential revenue generation

if you believe you buy or stay on board

-- First commercial deals signed across two technology channels - skin care and food supplement
-- Finalised formulation for food supplement to target psoriasis ready for human study and potential commercialisation

-- Active skin care ingredient development on track with partner, Croda plc, with commercialisation expected in 2022

-- Cash as at 30 June 2020 of GBP2.2m (2019: GBP3.1m)
-- Post year end: successful placing and open offer raising GBP4.45m





if you dont you sell up

interestingly in America Companies are not valued on profits ,rather the potential to increase revenue

[buywell3] 04/12/2020 08:40

Results RNS --- bottom line for buywell is :

SBTX made a loss before tax of £1,620k (2019: £1,360k).

ie losses increased by 19.1%